HCC will construct a superstructure of Bogibeel rail-cum-road bridge in Assam in 48 months
Leading engineering and construction firm Hindustan Construction Company (HCC) said its joint venture firm HCC-DSD-VNR has bagged a Rs987 crore order from the Northeast Frontier Railway to construct a superstructure of Bogibeel rail-cum-road bridge in Assam.
HCC's share in this order is 51%, Germany's DSD Brouckenbau has 20% and VNR Infrastructures gets the remaining 29%, a company statement said.
"This is one of the modern bridges over the Brahmaputra near Dibrugarh and HCC, along with its joint venture partners, is committed to build a world-class infrastructure for the Railways. The work on this superstructure will be completed in 48 months," HCC president and whole-time director Arun Karmabelkar said.
The 4.31-km long bridge will be double decked, having two railway tracks on the lower deck and a three-lane road on the upper deck. The road level will be 10.5 meters above the railway line. This will be the country's fourth largest bridge and the longest over the Brahmaputra, he added.
According to IMS data, the US market for generic Carboplatin is worth nearly $35 million, while it stands at about $1.4 billion for Oxaliplatin
Drug firm Strides Arcolab said it has received approval from the US health regulator to market two generic cancer drugs in the American market.
Onco Therapies Ltd, a unit of Strides Arcolab, has received approval from the US Food and Drug Administration (USFDA) for marketing injectable Carboplatin and tentative approval for marketing Oxaliplatin USP for injections, the company said in a statement.
The company has received a nod for marketing Carboplatin injections in strengths of 10 mg/mL (aqueous solution), packaged in 1,000 mg/100 mL pharmacy bulk packages. In addition, it has tentative approval for marketing Oxaliplatin in 50-mg and 100-mg single-use vials, it added.
According to IMS data, the US market for generic Carboplatin is worth nearly $35 million, while it stands at about $1.4 billion for Oxaliplatin.
“Carboplatin is part of the oncology portfolio licenced to Pfizer in January 2010, for the US market and is expected to be launched shortly,” the company said.
The company had earlier received approval for Carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials, it said.
Carboplatin injection is indicated for the initial treatment of advanced ovarian cancer, while Oxaliplatin is used to treat advanced cancer of the colon and rectum.
According to the report, the current US and the Euro zone crisis will keep the gold prices bullish and they are likely to reach $2,000 an ounce in another 3-4 months
Gold prices are likely to touch $2,000 by March, driven by the global economic crisis, while gold imports may reach 1,000 tonne, a senior SocotiaMocatta official on Thursday said.
"Investor demand has compensated the decline in the jewellery consumption. The rising gold prices, which has boosted the investors appetite, may result in close to 1,000 tonne imports of the yellow metal," Rajan Venkatesh, managing director, India bullion, SocotiaMocatta, a part of the Bank of Nova Scotia, said on the sidelines of FICCI 'Gems and Jewellery Conference'.
The current US and the Euro zone crisis, he said, will keep the gold prices bullish and they are likely to reach $2,000 an ounce in another 3-4 months.
"People are losing faith in cash as load of the US currency can be printed," he said.
The gold prices today in India ruled at Rs28,500 per 10 grams, while it was $1,695.90 an ounce in the global markets.
On silver, Venkatesh said, the imports will be slightly lower than last year's 3,030 tonnes due to the rise in prices.
"Silver business is not that significant (by volume)... a couple of months ago it was very good when prices had tapered off," he said.
The demand will improve if the silver prices come down to Rs40,000-Rs45,000 a kg, he said.
Silver prices today stood at Rs56,250 per kg here and in the global markets it was at $31.88 an ounce.